


Evolva completes Allylix acquisition

16 December 2014 | News | By BioSpectrum Bureau

Evolva completes Allylix acquisition



Evolva Holding announces the completion of the acquisition of Allylix, after which the acquired company will be a wholly-owned subsidiary of Evolva.

This transaction is in return for an overall consideration of 46 million newly-issued Evolva shares (c. 14.1 percent of Evolva post transaction). Part of these shares, currently estimated at approx. 6 million shares, will be sold over a period of time after closing, to offset certain liabilities and transaction expenses of Allylix. Shares allocated to the Allylix security holders will be subject to a staggered lock-up, such that the shares will be released in twelve tranches of approx. 3 million shares each, during the first year after the closing of the transaction.

The SIX Swiss Exchange has approved the listing of the new Evolva shares and trading in the new shares on the Main Standard of SIX is expected to commence soon.